DBV Technologies (NASDAQ:DBVT) shares surged 7.2% in premarket trading on Wednesday after the French biopharmaceutical company announced the completion of the final patient visit in its Phase 3 VITESSE trial evaluating the VIASKIN Peanut patch.
The study assesses the efficacy and safety of the VIASKIN Peanut patch in children aged 4 to 7 years with peanut allergies. With the double-blind, placebo-controlled treatment phase now concluded, DBV confirmed it remains on schedule to release topline data in the fourth quarter of this year.
“Last patient last visit represents a very important milestone for DBV, as it brings us one step closer to the potential of bringing this treatment option to peanut allergic children, their physicians and caregivers, if approved,” said Daniel Tassé, Chief Executive Officer of DBV Technologies.
The VITESSE Phase 3 trial enrolled 654 participants randomized in a 2:1 ratio across 86 clinical sites in the U.S., Canada, Europe, the U.K., and Australia. According to DBV, it is currently the largest interventional study ever conducted in peanut allergy.
The company’s VIASKIN Peanut patch is being developed as a non-invasive, daily immunotherapy treatment for children with peanut allergies — a potentially life-threatening condition affecting millions of patients worldwide.